{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:09:14Z","timestamp":1792843754914,"version":"4.5.0"},"reference-count":25,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014926","name":"Acceleron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pulmonary arterial hypertension is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the growth-promoting and growth-inhibiting signalling pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This\n                      <jats:italic>post hoc<\/jats:italic>\n                      , exploratory, pooled analysis combines data from the double-blind placebo periods of the phase 2 PULSAR (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03496207\">NCT03496207<\/jats:ext-link>\n                      ) and phase 3 STELLAR (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04576988\">NCT04576988<\/jats:ext-link>\n                      ) studies. Both studies were international, multicentre, randomised, double-blind, placebo-controlled trials in patients with pulmonary arterial hypertension. Efficacy and safety parameters common to both studies were analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 429 patients were randomised and treated; 237 received sotatercept and 192 received placebo. Adding sotatercept to background pulmonary arterial hypertension therapy for 24\u2005weeks improved exercise capacity (as assessed by 6-min walk distance), pulmonary vascular resistance and World Health Organization functional class, and delayed time to first occurrence of death or clinical worsening event. There were clinically important reductions in both pulmonary and right heart pressures; improvements in right ventricle size during both systole and diastole; and enhancements in right ventricle contractility and right ventricular\u2013pulmonary artery coupling. The number of patients who experienced at least one adverse event of interest or special interest (increased haemoglobin, thrombocytopenia, bleeding events (mostly epistaxis), increased blood pressure and telangiectasia) was higher in the sotatercept group than the placebo group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pooled analysis confirms that sotatercept delivers therapeutic benefit across a range of efficacy end-points and has favourable safety in patients with pulmonary arterial hypertension. Increased duration of follow-up will provide further insight into long-term outcomes of sotatercept in patients with pulmonary arterial hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01424-2024","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T12:15:18Z","timestamp":1738239318000},"page":"2401424","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies"],"prefix":"10.1183","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-2293","authenticated-orcid":false,"given":"Marius M.","family":"Hoeper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardi","family":"Gomberg-Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Badesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon R.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Kope\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1378-7362","authenticated-orcid":false,"given":"Ioana R.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-9143","authenticated-orcid":false,"given":"Rogerio","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7797-0361","authenticated-orcid":false,"given":"Aaron B.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Perchenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Strait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwen","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solaiappan","family":"Manimaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra G.","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janethe","family":"de Oliveira Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2029-4419","authenticated-orcid":false,"given":"H. Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025050701000788000_65.5.2401424.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.006974"},{"key":"2025050701000788000_65.5.2401424.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018"},{"key":"2025050701000788000_65.5.2401424.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022"},{"key":"2025050701000788000_65.5.2401424.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01347-2022"},{"key":"2025050701000788000_65.5.2401424.5","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.3390\/ijms19092585","article-title":"TGF-\u03b2 and BMPR2 signaling in PAH: two black sheep in one family","volume":"19","author":"Rol","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025050701000788000_65.5.2401424.6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4103\/2045-8932.87293","article-title":"The genetics of pulmonary arterial hypertension in the post-BMPR2 era","volume":"1","author":"Fessel","year":"2011","journal-title":"Pulm Circ"},{"key":"2025050701000788000_65.5.2401424.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2011.87"},{"key":"2025050701000788000_65.5.2401424.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02341-2020"},{"key":"2025050701000788000_65.5.2401424.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061501"},{"key":"2025050701000788000_65.5.2401424.10","doi-asserted-by":"publisher","DOI":"10.1042\/CS20190835"},{"key":"2025050701000788000_65.5.2401424.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00486-7"},{"key":"2025050701000788000_65.5.2401424.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.010"},{"key":"2025050701000788000_65.5.2401424.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01726-2023"},{"key":"2025050701000788000_65.5.2401424.14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12838"},{"key":"2025050701000788000_65.5.2401424.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"2025050701000788000_65.5.2401424.16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"2025050701000788000_65.5.2401424.17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213558"},{"key":"2025050701000788000_65.5.2401424.18","unstructured":"US Food and Drug Administration . WINREVAIR\u2122 (sotatercept-csrk) For Injection, For Subcutaneous Use. 2024. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761363s000lbl.pdf Date last updated: 26 March 2024. Date last accessed: 19 April 2024."},{"key":"2025050701000788000_65.5.2401424.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01107-2023"},{"key":"2025050701000788000_65.5.2401424.20","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00520-015-2929-9","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025050701000788000_65.5.2401424.21","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3468"},{"key":"2025050701000788000_65.5.2401424.22","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.160"},{"key":"2025050701000788000_65.5.2401424.23","unstructured":"ClinicalTrials.gov . A Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality (ZENITH). Date last accessed: 19 April 19 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04896008"},{"key":"2025050701000788000_65.5.2401424.24","unstructured":"ClinicalTrials.gov . Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients (HYPERION). Date last accessed: 19 April 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04811092"},{"key":"2025050701000788000_65.5.2401424.25","unstructured":"ClinicalTrials.gov . A Long-Term Follow-Up Study of Sotatercept for PAH Treatment (SOTERIA). Date last accessed: 19 April 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04796337"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01424-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T04:00:15Z","timestamp":1746590415000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01424-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,6]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1183\/13993003.01424-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01424-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}